<DOC>
	<DOCNO>NCT01641510</DOCNO>
	<brief_summary>The investigator hypothesize reduce load dose prasugrel follow reduced maintenance dose prasugrel acute coronary syndrome patient CYP2C19 polymorphism undergo percutaneous coronary intervention might exhibit low platelet reactivity 24 hour 30 day later associate major adverse cardiovascular event .</brief_summary>
	<brief_title>PRAsugrel clopIdogrel Acute Coronary SyndromE Patients With CYP2C19 Polymorphism</brief_title>
	<detailed_description>Antiplatelet treatment recommend worldwide secondary prevention clopidogrel essential drug . But clopidogrel limit value pharmacodynamic interpatient variability delay onset time . It well known patient carry common reduced-function CYP2C19 allele low level active metabolite clopidogrel , diminish platelet inhibition , furthermore , high rate major adverse cardiovascular event noncarriers . To achieve maximum plateau rapidly reduce rate high on-treatment platelet reactivity , high load dose clopidogrel , 600 mg , recommend . Although , however , high load dose clopidogrel , many patient still remain non-responder . Incidence patient clopidogrel resistance , especially CYP2C19*2 *3 , encounter loss function , high Eastern Asian people Western people . Some study report incidence rate clopidogrel resistance Eastern Asian people 99 % . However , metabolism influence presence CYP2C19 genetic variation prasugrel show potent platelet inhibition . Although prasugrel exhibit potent platelet inhibition , recent report describe possible inhibition platelet especially East Asian people . The investigator go compare efficacy safety load dose prasugrel 30 mg low conventional loading dose follow 5 mg/day also low conventional maintenance dose 30 day load dose clopidogrel 600 mg follow 75 mg/day 30 day .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Acute coronary syndrome Patients plan undergo percutaneous transluminal coronary angioplasty Patients agree experimental plan permit IRB Low body weight ( &lt; 50kg ) History stroke transient ischemic attack History upper gastrointestinal bleeding recent 6 month Renal dysfunction define serum creatinine &gt; 2.5 mg/dl Severe hepatic dysfunction define ChildPugh criterion B C Bleeding tendency Anticoagulation treatment include warfarin Thrombocytopenia define platelet &lt; 100,000/ml Anemia define hemoglobin &lt; 10 g/dl Contraindication antiplatelet treatment anticoagulation treatment History administer glycoprotein IIb/IIIa inhibitor recent 24hrs plan</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>reduced-function CYP2C19 allele</keyword>
	<keyword>high platelet reactivity</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>prasugrel</keyword>
</DOC>